Subtleties, flaws, questions [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2011-03-27 22:35 (5180 d 15:07 ago) – Posting: # 6818
Views: 39,927

Dear D. Labes!

Source         DF   Type III SS   Mean Square  [...]


sequence        0    0.0000000    .            [...]

[...]


Zero degrees of freedom is not a lot.
I love SAS‘s ‘.’ - Phoenix/WinNonlin spits out ‘Not estimable’, but I can trim it to ‘.’ or even ‘0’… :-D

Open issues IMHO:
  • Outliers – which method? Model residuals or R/R ratios?
  • Obviously EMA is not interested in CVWT (Method C) at all. Since GLM throws away incomplete data (Method A), why should one go with a full replicate design? More periods, more chances of drop-outs.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,679 registered users;
24 visitors (0 registered, 24 guests [including 19 identified bots]).
Forum time: 13:42 CEST (Europe/Vienna)

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5